• Medicine
  • Published in Bulletin du cancer 2005

[Pharmacological skills for targeting EGFR and VEGF].

@article{Milano2005PharmacologicalSF,
  title={[Pharmacological skills for targeting EGFR and VEGF].},
  author={G{\'e}rard A. Milano},
  journal={Bulletin du cancer},
  year={2005},
  volume={92 Spec no},
  pages={
          S17-20
        }
}
Several monoclonal antibodies directed against EGFR are currently in clinical evaluation and include notably the agent cetuximab (C225). Tyrosine kinase inhibitors have chemical structures close to that of ATP and are thus ATP competitors on the tyrosine kinase site (ATP pocket) which is located in the intracellular domain of EGFR (gefitinib and erlotinib, respectively Tarceva and Iressa being the most advanced in clinical development). Well-conducted experimental studies open the way to new… CONTINUE READING